a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer
Industry Biotechnology
A.I.dvisor tells us that FBRX and CLNN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FBRX and CLNN's prices will move in lockstep.
Ticker / NAME | Correlation To FBRX | 1D Price Change % | ||
---|---|---|---|---|
FBRX | 100% | -1.59% | ||
CLNN - FBRX | 32% Poorly correlated | -2.70% | ||
VRCA - FBRX | 26% Poorly correlated | +2.11% | ||
FBIO - FBRX | 25% Poorly correlated | -4.85% | ||
FDMT - FBRX | 23% Poorly correlated | +4.02% | ||
AVCTF - FBRX | 23% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To FBRX | 1D Price Change % |
---|---|---|
FBRX | 100% | -1.59% |
treatment theme (56 stocks) | 18% Poorly correlated | -4.37% |
gene therapy theme (12 stocks) | 18% Poorly correlated | -6.36% |
cancer theme (82 stocks) | 17% Poorly correlated | -5.41% |